RIGVIR® contains an adapted live enterovirus, which is oncotropic and oncolytic, nonpathogenic, genetically not modified. RIGVIR® does not contain antibiotics, stimulants, potentially toxic substances.
RIGVIR® demonstrates outstanding safety profile. About 2000 patients participated in various RIGVIR® clinical studies; half in safety, half in efficacy studies. No serious adverse events were recorded, the most common symptom was subfebrile temperature.